Trial · NCT06047080
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080, Phase 3, Active not recruiting, Hoffmann-La Roche
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma. Trials, record NCT06047080. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06047080
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- NCT number
- NCT06047080
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 1,130 participants, actual
- Lead sponsor
- Hoffmann-La Roche
- Conditions
- Large B-Cell Lymphoma
- Interventions
- Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- First posted
- 2023-09-21
- Last updated
- 2026-09-11
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) as determined by Independent Review Facility (IRF) | From randomization to the first occurrence of disease progression or relapse, or death due to any cause, whichever occurs first (up to approximately 65 months) | |
| Secondary | PFS as determined by the investigator | From randomization to the first occurrence of disease progression or relapse or death from any cause, whichever occurs first (up to approximately 65 months) | |
| Secondary | PFS as determined by the investigator and IRF for participants with international prognostic index (IPI) 3-5 | From randomization to the first occurrence of disease progression or relapse or death from any cause, whichever occurs first (up to 65 months) | |
| Secondary | Event-free survival efficacy causes (EFSeff) | From randomization to the earliest occurrence of disease progression or relapse; death due to any cause; initiation of new anti-lymphoma treatment; or positive biopsy for residual disease after treatment completion (up to approximately 65 months) | |
| Secondary | Complete response (CR) rate | At the end of treatment (up to approximately 65 months) | |
| Secondary | Objective response rate (ORR) | At treatment completion or discontinuation (up to approximately 65 months) | |
| Secondary | Overall survival (OS) | From randomization to death from any cause (up to approximately 65 months) | |
| Secondary | Duration of response (DOR) | From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 65 months) | |
| Secondary | Duration of complete response (DOCR) | From the first occurrence of a documented complete response (CR) to disease progression or death, whichever occurs first (up to approximately 65 months) | |
| Secondary | Disease-free survival (DFS) | From a documented CR at the end of treatment to disease progression or death, whichever occurs first (up to approximately 65 months) |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06047080
GET https://conductscience.org/api/trials/v1/NCT06047080/registered